Literatura académica sobre el tema "VIH/Hépatite C"
Crea una cita precisa en los estilos APA, MLA, Chicago, Harvard y otros
Consulte las listas temáticas de artículos, libros, tesis, actas de conferencias y otras fuentes académicas sobre el tema "VIH/Hépatite C".
Junto a cada fuente en la lista de referencias hay un botón "Agregar a la bibliografía". Pulsa este botón, y generaremos automáticamente la referencia bibliográfica para la obra elegida en el estilo de cita que necesites: APA, MLA, Harvard, Vancouver, Chicago, etc.
También puede descargar el texto completo de la publicación académica en formato pdf y leer en línea su resumen siempre que esté disponible en los metadatos.
Artículos de revistas sobre el tema "VIH/Hépatite C"
Bawè, LD y Et Al. "Prévalence des marqueurs infectieux chez les donneurs de sang au centre régional de transfusion sanguine de Sokodé". Revue Malienne d'Infectiologie et de Microbiologie 18, n.º 2 (8 de enero de 2024): 26–32. http://dx.doi.org/10.53597/remim.v18i2.2731.
Texto completoIlboudo, D., A. Sawadogo y J. Simpore. "Co-infection hépatite C et VIH chez les femmes enceintes à Ouagadougou (Burkina Faso)". Médecine et Maladies Infectieuses 33, n.º 5 (mayo de 2003): 278–79. http://dx.doi.org/10.1016/s0399-077x(02)00004-5.
Texto completoBaud, O., H. Laurichesse, V. Chanet, C. Henquell, F. Gourdon, S. Dydymski, L. Cormerais y J. Beytout. "Cirrhose hépatique : cause émergente de décès chez les patients atteints de co-infection VIH et hépatite chronique B ou C". La Revue de Médecine Interne 19 (enero de 1998): 448. http://dx.doi.org/10.1016/s0248-8663(98)90160-6.
Texto completoPesce, A., B. Taillan, G. Garnier, E. Rosenthal, H. Vinti y JP Cassuto. "Infections opportunistes et lymphopénie CD4 chez des patients VIH+ traités par interféron pour hépatite C". La Revue de Médecine Interne 14, n.º 10 (enero de 1993): 1091. http://dx.doi.org/10.1016/s0248-8663(05)80205-x.
Texto completoTarasuk, Jill, Meghan Sullivan, Donna Bush, Christian Hui, Melissa Morris, Tami Starlight, François Cholette et al. "Résultats en ce qui concerne les participants autochtones sondés dans le cadre de l'enquête Track auprès des utilisateurs de drogues injectables au Canada, phase 4, 2017 à 2019". Relevé des maladies transmissibles au Canada 47, n.º 1 (29 de enero de 2021): 43–55. http://dx.doi.org/10.14745/ccdr.v47i01a07f.
Texto completoBossali, F., R. Taty-Taty, P. Houssissa, W. N’suele, L. G. Lingouala, E. N. Ontsira y Obengui. "Séroprévalence de la co-infection hépatite B, hépatite C et VIH chez des femmes accouchées à la maternité de l’hôpital Adolphe Sicé de Pointe-Noire en 2010". Journal Africain d'Hépato-Gastroentérologie 6, n.º 4 (14 de julio de 2012): 315–19. http://dx.doi.org/10.1007/s12157-012-0424-1.
Texto completoSogni, P., D. Salmon-Céron y P. Podevin. "Prise en charge des complications de la cirrhose chez les patients VIH co-infectés par une hépatite virale B ou C". La Presse Médicale 34, n.º 20 (noviembre de 2005): 1579–83. http://dx.doi.org/10.1016/s0755-4982(05)84228-9.
Texto completoOuedraogo, M. S., S. Bara/Tiendrebeogo, P. G. Tapsoba, N. Korsaga/Some, A. N. Ouedraogo, L. Tiendrebeogo, A. Yameogo, F. Barro/Traoré, P. Niamba y A. Traoré. "CO 13 : Coïnfection VIH/ Hépatite B et C chez les personnes vivant avec le VIH dans une structure associative de prise en charge médicale de la ville de Ouagadougou (BURKINA FASO)". Annales de Dermatologie et de Vénéréologie 143, n.º 4 (abril de 2016): S25. http://dx.doi.org/10.1016/s0151-9638(16)30140-5.
Texto completoPerronne, C., F. Carrat, F. Bani-Sadr, S. Pol, E. Rosenthal, F. Lunel, P. Morand et al. "CL4-04 RIBAVIC ANRS HC02: essai thérapeutique évaluant l'efficacité et la tolérance de l'interféron (PEG-IFN α2b versus IFN α2b) en association avec la ribavirine chez les patients porteurs d'une hépatite chronique C non traitée et coinfectés par le VIH". Médecine et Maladies Infectieuses 34 (junio de 2004): S80. http://dx.doi.org/10.1016/s0399-077x(04)90049-2.
Texto completoPaternoster, Morgane, Boulfa Badoro, Chloé Bourovali-Zade, Christine Castera, Hugues Cordel, Soline de Monteynard, Christiane Hocde et al. "Dépistage des hépatites au sein d’une association culturelle et cultuelle pakistanaise : retour d’expérience". Santé Publique 36, n.º 3 (21 de junio de 2024): 39–48. http://dx.doi.org/10.3917/spub.243.0039.
Texto completoTesis sobre el tema "VIH/Hépatite C"
Di, Martino Vincent. "Histoire naturelle de l'hépatite C chez les patients immunodéprimés". Paris 7, 2001. http://www.theses.fr/2001PA077185.
Texto completoGuitton, Emmanuelle. "Influence de la co-infection virale chez les patients VIH : approche pharmacoépidémiologique". Toulouse 3, 2006. http://www.theses.fr/2006TOU30280.
Texto completoHepatitis C infection (HCV) concerns 10% to 30% of HIV patients. The aim of our research was to explore the influence of HCV co infection in HIV patients with data from the French Pharmacovigilance database and from a regional cohort of HIV and coinfected patients. We showed that hepatic or haematological troubles occurred more frequently in coinfected patients. In the cohort study, clinical and immunological worsening of HIV infection seems to be faster in co infected patients, despite the lack of statistically significant difference. This work underlines the differences in the therapeutic management of the HIV and HIV+HCV patients (ARV drugs, modifications or withdrawal of ARV drugs). The risk of the occurrence of hepatic or haematological troubles with ARV drugs is a possible explanation. The cohort should be continued to increase the number of patients included
Couturier, Sarah. "Synthèse et étude de 3'-desoxy-3'-C-methylnucléosides pyrimidiques". Montpellier 2, 2004. http://www.theses.fr/2004MON20183.
Texto completoNeau, Didier. "Aspects viro-immunologiques de l'hépatite chronique C au cours de l'infection par le VIH". Bordeaux 2, 2001. http://www.theses.fr/2001BOR28865.
Texto completoHCV infection is frequent and potentially severe in HIV-infected patients. In order to better understand the interactions between an immunocompromised host and HCV, different virological and immunological aspects of HCV-HIV were investigated. In the context of a clinical trial concerning 68 patients, we evaluated the efficacy of anti-HCV-treatment in HIV infection. We studies 1) the kinetics of plasma HCV load under interferon and its relationship with intra-hepatic HCV load 2) HCV variability (complexity and diversity of quasispecies) 3) TCD4 proliferative responses to HCV antigens, HIV p24, and tuberculin, to evaluate the predictive value of these different parameters on the response to anti-HCV treatment. Our results showed that the kinetics of HCV load under therapy in HIV coinfection was not significantly different of that observed in immunocompetent patients. Plasma load correlated with intra-hepatic load, which was significantly lower in patients treated with a protease inhibitor at the time of the biopsy. Plasma HCV quasispecies complexity before treatment was comparable with that observed in a group of HCV-infected patients. In contrast with immunocompetent patients, it did not predict response to treatment. Anti-HCV treatment modified the profile of quasispecies in 70 % of the patients. Genetic diversity was different according to the genotype. Initial proliferative response to HCV antigens did not predict the efficiency of the treatment. However, a profile of persisting immunological responders was significantly associated with viral clearance during immunological sequential follow-up
Laouénan, Cédric. "Utilisation des modèles dynamiques pour l'évaluation des traitements de l'hépatite C". Paris 7, 2014. http://www.hal.inserm.fr/tel-01077435.
Texto completoSince 2011, the introduction of triple therapies combining a protease inhibitor (PI), telaprevir or boceprevir, with the pegylated-interferon and the ribavirin (Peg-IFN/RBV) marked a milestone for anti hepatitis C virus (HCV) therapy. However, the response to treatment in cirrhotic patients remains unclear and poses serious safety problems. Vira kinetic models, analyzed by nonlinear mixed effect models (NLMEM), are a powerful tool for understanding the response to treatment. We have demonstrated, by means of clinical trial simulation, the power of the Wald tes1 within NLMEM to detect a HCV drug's antiviral effectiveness difference. This approach, even for a small number of samples, provided consistently higher power to the standard approach based on a non parametric Wilcoxon test on the viral load decay. However, we have highlighted an inflation of the type I error with the Wald test when the number of patients is low and have proposed a permutation correction. We applied this approach to estimate the antiviral effectiveness of the triple therapies in cirrhotic patients and non-responders to a prior therapy (ANRS MODCUPIC). We hav( shown that over 99% of the viral replication was blocked by PI, with a significantly superior effectiveness of telaprevir compared to boceprevir and suboptimal effectiveness of Peg-IFN/RBV. Finally, by modeling the kinetics of blood parameters, we demonstrated that the concentrations of Peg-IFN and RBV are associated with, respectively, anemia and thrombocytopenia which are frequently observed in these patients
Marcellin, Fabienne. "Perceptions et comportements des personnes vivant avec le VIH co-infestées par le virus de l'hépatite C". Thesis, Aix-Marseille, 2016. http://www.theses.fr/2016AIXM5001.
Texto completoBetween 25,000 and 30,000 people are co-infected with HIV and hepatitis C virus (HCV) in France, with major clinical repercussions. Major therapeutic advances have been made in recent years thanks to the development of direct-acting antivirals for HCV treatment, with very good efficacy and safety profiles. In the same time, while the number of co-infected patients has globally decreased among HIV-infected patients, new groups at risk of HCV transmission have emerged in this population, such as men who have sex with men (MSM). Co-infected patients’ day-to-day experience with the disease remains poorly documented. In this work, we analyze the perceptions (quality of life, functional impact of fatigue) and behaviors (sexual risk behaviors, addictive behaviors) of co-infected patients and their relationships with clinical parameters, and we try to determine to what extent such data can be used to improve the management of co-infection and to better target HCV prevention actions
Schnuriger, Aurélie. "Etude des caractéristiques immunologiques et virologiques associées à la guérison de l'infection par le virus de l'hépatite C au cours d'une infection par le VIH". Paris 6, 2007. http://www.theses.fr/2007PA066262.
Texto completoAlatrakchi, Nadia. "Etude des réponses cellulaires th1 au cours des infections persistantes à VIH-1 et virus apparentés (VIH-2) ou associés (VHC)". Paris 7, 2005. http://www.theses.fr/2005PA077193.
Texto completoTo better understand the role of the immune responses in persistent chronic viral infections, I studied T cell immune responses, especially Thl, in persistent infections such as HIV-1, related virus such as HIV-2 or associated virus such as HCV. Three models of HIV infection with a relative control of virus replication were chosen: long term non progressors of HIV-1 infection co-infected with HCV, stable partially controlled subjects with HIV-1 infection during antiretroviral therapy; and subjects with HIV-2 infection. Strong virus specific Thl responses were found in the 3 groups of subjects and were associated with strong anti-viral CD8 T cell responses. Indeed, these virus specific T cell responses were inversely associated to the virus replication. Altogether these data emphasize the crucial role of Thl in maintaining efficient CD8 responses, therefore suggesting their contribution to maintain the balance between the host and the virus during chronic viral infections such as HIV or HCV
Dichamp, Isabelle. "Pathogenèse de l'infection à VIH-1 : rôle des protéines virales Tat et Nef". Besançon, 2006. http://www.theses.fr/2006BESA0006.
Texto completoWe demonstrated the effect of the second codmg exon ofTat to the control ofHIV-1 NF-κB¬ dependent and TAR-independent HIV-1 transcription in T cells. Thus, our results show an important role of the second coding exon of Tat in the activation of NF -κB, the HIV -1 LTR : stimulation, resulting in enhanced viral replication in T cells. During HIV ffiCV coinfections, we demonstrated that the HCV Core protein via interaction with HIV-1 Nef could enhance the NF-κB activation and the HIV-1 LTR stimulation mediated by HIV-1 Nef. Thus, the size of the viral macrophagic reservoirs could be increased for the two yiruses. Nef is a : multifunctional protein which interacts with cellular and viral proteins. By different experiments, we demonstrated that HIV -1 Nef protèin interacts specifically and directly with EFIA2 both in vitro and in vivo
Hagège, Meoïn. "Sortir et s'en sortir ? : parcours de santé et vulnérabilités de sortants de prison qui vivent avec le VIH ou une hépatite C". Paris, EHESS, 2016. http://www.theses.fr/2016EHES0096.
Texto completoThe health of inmates and released inmates is a public health problem seldom studied in France. The case study of men living with HIV and/or hepatitis C in the greater Parisian region is central to this PhD research. It aims to shed light on the life course and health trajectories before, during and after incarceration. These trajectories are constructed from data gathered through a three-pronged field work (observation, a series of biographical interviews and a survey). The study was conducted in and outside of prison to describe prisoners' experiences of care and treatment and the work done by healthcare and social work professionals. Hepatitis C is considered less important and severe than HIV, which explains the more frequent delays in recourse to care upon release and less challenging and stigmatizing experiences of the illness. Treatment interruptions are short and are part of the multiple adjustments that patients undertake to cope with release. These adjustments involve the tedious administrative procedures to (re)gain access to health and social welfare but also an embodied experience of release, (re)negotiation of personal and professional relationships. The interactions between the released inmates, their kin and the professionals who take care of them are described within the power structures in which they are embedded. In their institutional experience, patients are simultaneously regarded as subjects meant to interiorize health norms and asked to become self-reliant responsible individuals. Lastly, the trajectories of these men and women are inscribed in a process of progressing social vulnerability, exacerbated by HIV and HCV status, incarcerations and their release from prison. Prison release is lived as a liminal moment in the trajectories, as they pass from prison back into the city. The temporality is particular: it is constructed around activities and support relationships rather than based on linear chronological time; as a result prison release is full of uncertainty and seems interminable
Libros sobre el tema "VIH/Hépatite C"
Jürgens, Ralf. Le VIH/sida en milieu carcéral: Une bibliographie sélective et annotée. Ottawa, Ont: Direction des affaires internationales, Santé Canada, 2005.
Buscar texto completoCook, Catherine. The global state of harm reduction 2008: Mapping the response to drug-related HIV and hepatitis C epidemics. London: International Harm Reduction Association, 2008.
Buscar texto completoNetwork, Canadian Harm Reduction. Learning from each other: Enhancing community-based harm reduction programs and practices in Canada. Ottawa, Ont: Canadian AIDS Society, 2008.
Buscar texto completoPsychiatrie, VIH et hépatite C. Elsevier, 2009. http://dx.doi.org/10.1016/b978-2-294-70852-7.x5000-2.
Texto completoLang, Jean-Philippe, Agence Française De Sécurité Sanitaire D, Ahmed Ananna y François Bailly. Psychiatrie, VIH et Hépatite C: Quels Enjeux de Santé Publique ? Quels Enjeux Pour la Psychiatrie ? Elsevier Masson SAS Éditeur, 2011.
Buscar texto completoCapítulos de libros sobre el tema "VIH/Hépatite C"
Darreye, Angélina, Aurica Stroescu, Jean-Philippe Lang y Christophe Hézode. "Cannabis, VHC et VIH". En Psychiatrie, VIH et hépatite C, 130–37. Elsevier, 2009. http://dx.doi.org/10.1016/b978-2-294-70852-7.50015-3.
Texto completoMichel, Laurent, Jean-Philippe Lang y Gilles Pialoux. "Situation épidémiologique actuelle du VIH et du VHC en France". En Psychiatrie, VIH et hépatite C, 3–7. Elsevier, 2009. http://dx.doi.org/10.1016/b978-2-294-70852-7.50001-3.
Texto completoLang, Jean-Philippe, Laurent Michel, Pascal Melin, Marc Schoeffler, Aurélie Gauchet, Véronique Cartier y Chantal Henry. "État des lieux de la prise en charge psychiatrique et psychologique des patients VHC+ et VIH/VHC+ en France". En Psychiatrie, VIH et hépatite C, 8–15. Elsevier, 2009. http://dx.doi.org/10.1016/b978-2-294-70852-7.50002-5.
Texto completoGrosshans, Daniel y Isabelle Galland. "Clinique psychologique de l'adulte infecté par le VIH". En Psychiatrie, VIH et hépatite C, 19–28. Elsevier, 2009. http://dx.doi.org/10.1016/b978-2-294-70852-7.50003-7.
Texto completoJacques, Gasnault y Lang Jean-Marie. "Les manifestations neurologiques au cours de l'infection par le VIH". En Psychiatrie, VIH et hépatite C, 29–36. Elsevier, 2009. http://dx.doi.org/10.1016/b978-2-294-70852-7.50004-9.
Texto completoRoux, Perrine, Laurent Michel y Jean-Philippe Lang. "Implications des troubles psychiatriques et des addictions sur l'observance et la qualité de vie des patients co-infectés par le VIH et le VHC". En Psychiatrie, VIH et hépatite C, 37–43. Elsevier, 2009. http://dx.doi.org/10.1016/b978-2-294-70852-7.50005-0.
Texto completoCherikh, Faredj y Pierre Dellamonica. "Implication des troubles psychiatriques sur l'observance et la tolérance aux traitements antirétroviraux". En Psychiatrie, VIH et hépatite C, 44–52. Elsevier, 2009. http://dx.doi.org/10.1016/b978-2-294-70852-7.50006-2.
Texto completoKel, Charles-Louis, Mathieu Lacambre, Jean-Philippe Lang y Jean-Marie Lang. "Troubles psychiatriques et infection par le VIH". En Psychiatrie, VIH et hépatite C, 53–61. Elsevier, 2009. http://dx.doi.org/10.1016/b978-2-294-70852-7.50007-4.
Texto completoConstant, Aymery y Laurent Castera. "Impact psychologique de l'annonce du diagnostic d'hépatite chronique C". En Psychiatrie, VIH et hépatite C, 65–71. Elsevier, 2009. http://dx.doi.org/10.1016/b978-2-294-70852-7.50008-6.
Texto completoGreth, Philippe, Aurica Stroescu y François Sellal. "Les complications neurologiques et cognitives de l'hépatite C". En Psychiatrie, VIH et hépatite C, 72–79. Elsevier, 2009. http://dx.doi.org/10.1016/b978-2-294-70852-7.50009-8.
Texto completo